Athersys stem cell therapy wins scientists' plaudits

May 24, 2010 by MedCity News

Athersys Inc. wins plaudits from scientists for the potential of its its stem cell-based therapies for heart attack, stroke and spinal cord injury at its investors day in New York.

MedCity News logo

By Mary Vanac

Doctors and researchers at the Athersys Inc. (NSDQ:ATHX) investor meeting in New York City expressed hope that the company's stem cell therapy — MultiStem — could raise the ceiling on care for heart attack, stroke and some cancer patients, among others.

Get the complete picture with a MassDevice Plus membership. Registered users can login here.